Lilly's tirzepatide moves closer to slice of obesity market

27 April 2023

Eli Lilly’s (NYSE: LLY) tirzepatide moved a step closer to seizing a share of the obesity market on Thursday, when the US drugmaker’s shares were up by more than 2% in early trading.

The once-weekly glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist, which is currently sold for diabetes under the brand name Mounjaro, achieved superior weight loss compared to placebo at 72 weeks of treatment in results from SURMOUNT-2.

"The degree of mean weight reduction has not been previously achieved in Phase III trials for obesity or overweight and type 2 diabetes"This Phase III trial is evaluating the safety and efficacy of tirzepatide in adults who have obesity or are overweight, and type 2 diabetes.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK